These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 25131958)
1. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor. Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties. Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, docking and in vitro anticancer evaluation of some new benzopyrone derivatives. El-Ansary SL; Hussein MM; Abdel Rahman DE; Abdel Ghany LM Bioorg Chem; 2014 Apr; 53():50-66. PubMed ID: 24607350 [TBL] [Abstract][Full Text] [Related]
4. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R). Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696 [TBL] [Abstract][Full Text] [Related]
5. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Shi L; Wu TT; Wang Z; Xue JY; Xu YG Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and identification of unprecedented selective inhibitors of CK1ε. Silveira-Dorta G; Sousa IJ; Fernandes MX; Martín VS; Padrón JM Eur J Med Chem; 2015; 96():308-17. PubMed ID: 25899335 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846 [TBL] [Abstract][Full Text] [Related]
8. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity. Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525 [TBL] [Abstract][Full Text] [Related]
10. Guanidinium-based derivatives: searching for new kinase inhibitors. Diez-Cecilia E; Kelly B; Perez C; Zisterer DM; Nevin DK; Lloyd DG; Rozas I Eur J Med Chem; 2014 Jun; 81():427-41. PubMed ID: 24858546 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290 [TBL] [Abstract][Full Text] [Related]
13. Protein kinase casein kinase 2-mediated upregulation of N-cadherin confers anoikis resistance on esophageal carcinoma cells. Ko H; Kim S; Jin CH; Lee E; Ham S; Yook JI; Kim K Mol Cancer Res; 2012 Aug; 10(8):1032-8. PubMed ID: 22767590 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors. Parveen I; Khan P; Ali S; Hassan MI; Ahmed N Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues. Al-Suwaidan IA; Abdel-Aziz AA; Shawer TZ; Ayyad RR; Alanazi AM; El-Morsy AM; Mohamed MA; Abdel-Aziz NI; El-Sayed MA; El-Azab AS J Enzyme Inhib Med Chem; 2016; 31(1):78-89. PubMed ID: 25815668 [TBL] [Abstract][Full Text] [Related]
16. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181 [TBL] [Abstract][Full Text] [Related]
17. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors. El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754 [TBL] [Abstract][Full Text] [Related]
18. Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment. Jin F; Gao D; Zhang C; Liu F; Chu B; Chen Y; Chen YZ; Tan C; Jiang Y Bioorg Med Chem; 2013 Feb; 21(3):824-31. PubMed ID: 23260578 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents. Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors. Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]